<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793165</url>
  </required_header>
  <id_info>
    <org_study_id>5302</org_study_id>
    <nct_id>NCT04793165</nct_id>
  </id_info>
  <brief_title>Is the Artificial Pancreas, Without Carbohydrate Counting, Efficient and Safe in an Outpatient Setting</brief_title>
  <official_title>Is the Artificial Pancreas, Without Carbohydrate Counting, Efficient and Safe for Ambulatory Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Tecnológico de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Nacional de La Plata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Nuria/Cellex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, interventional clinical trial to assess the effectiveness and safety of&#xD;
      artificial pancreas (AP) using the ARG algorithm closed-loop system in a monitored 3-day&#xD;
      period outpatient study. Once the safety of the device has been validated in the open-loop&#xD;
      first 3-day period (continuous subcutaneous insulin infusion (CSII) plus continuous glucose&#xD;
      monitoring (CGM)) the investigators will move the study to the second 3-day closed-loop&#xD;
      period, without carbohydrate (CHO) counting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Actual">April 8, 2021</completion_date>
  <primary_completion_date type="Actual">March 14, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effectiveness and safety of AP treatment without CHO counting in an outpatient setting.</measure>
    <time_frame>3 days</time_frame>
    <description>Percent of time in each range according to sensor glucose readings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the percentage of time with glycemic levels from 70 to 180 mg/dl (time in range).</measure>
    <time_frame>3 days</time_frame>
    <description>Percent of time in the target range of 70-180 mg/dl according to sensor glucose readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine, as a safety parameter, the percentage of time with glycemic levels less than 70 mg/dl.</measure>
    <time_frame>3 days</time_frame>
    <description>Percent of time in range of less than 70 mg/dl according to sensor glucose readings</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Autoimmune Diabetes</condition>
  <arm_group>
    <arm_group_label>Non-hybrid closed-loop system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To compare two types of treatments:&#xD;
During the first 3 days: Previous or conventional, with CSII plus CGM in open loop.&#xD;
During the second 3 day period: AP with CSII plus CGM in a closed-loop system, through the ARG algorithm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-hybrid closed-loop system with ARG algorithm</intervention_name>
    <description>To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting</description>
    <arm_group_label>Non-hybrid closed-loop system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has been diagnosed with T1DM at least two years ago and has been using an&#xD;
             insulin pump and a CGM for at least 6 months prior to the trial first visit&#xD;
&#xD;
          -  Patient is &gt;18 and &lt;65 years&#xD;
&#xD;
          -  Patient has HbA1c &lt; 10%&#xD;
&#xD;
          -  Woman in premenopausal age agrees to use contraceptive methods&#xD;
&#xD;
          -  Woman in premenopausal age has negative B-HCG in the tests performed in the trial&#xD;
&#xD;
          -  Patient is trained in CHO counting&#xD;
&#xD;
          -  Patient has signed informed consent and has the ability to understand the nature and&#xD;
             intent of the study including the ability to comply with study procedures and is&#xD;
             willing to keep scheduled visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has been hospitalized for diabetic ketoacidosis in the last 12 months&#xD;
&#xD;
          -  Patient has experienced severe hypoglycemia with loss of consciousness in the last 12&#xD;
             months&#xD;
&#xD;
          -  Patient has a history of coronary disease or cardiac failure&#xD;
&#xD;
          -  Patient with uncontrolled arterial hypertension&#xD;
&#xD;
          -  Patient with a condition that makes the researcher believe that it might increase the&#xD;
             chance of hypoglycemia&#xD;
&#xD;
          -  Patient has symptoms compatible with active infectious disease&#xD;
&#xD;
          -  Patient has Cystic Fibrosis&#xD;
&#xD;
          -  Pregnant women, or women with the intention of getting pregnant; women breastfeeding&#xD;
&#xD;
          -  Patient has been hospitalized for psychiatric treatment in the last 6 months.&#xD;
&#xD;
          -  Patient with a diagnosis of adrenal disease&#xD;
&#xD;
          -  Patient has abnormal laboratory values for liver function: transaminase &gt; 2x upper&#xD;
             limit normal&#xD;
&#xD;
          -  Patient has abnormal laboratory values for renal function: GFR &lt; 60 ml/min/1.73m2&#xD;
&#xD;
          -  Patient has active gastroparesis&#xD;
&#xD;
          -  Patient is under oncological treatment&#xD;
&#xD;
          -  Patient has taken acetaminophen 72 hours previous to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis A Grosembacher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Sánchez-Peña R, Colmegna P, Garelli F, De Battista H, García-Violini D, Moscoso-Vásquez M, Rosales N, Fushimi E, Campos-Náñez E, Breton M, Beruto V, Scibona P, Rodriguez C, Giunta J, Simonovich V, Belloso WH, Cherñavvsky D, Grosembacher L. Artificial Pancreas: Clinical Study in Latin America Without Premeal Insulin Boluses. J Diabetes Sci Technol. 2018 Sep;12(5):914-925. doi: 10.1177/1932296818786488. Epub 2018 Jul 12.</citation>
    <PMID>29998754</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes technology</keyword>
  <keyword>T1DM</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>closed-loop</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

